S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
NYSE:EBS

Emergent BioSolutions - EBS Stock Forecast, Price & News

$7.79
-0.38 (-4.65%)
(As of 03/22/2023 12:00 AM ET)
Add
Compare
Today's Range
$7.77
$8.23
50-Day Range
$7.79
$16.29
52-Week Range
$7.77
$45.14
Volume
1.05 million shs
Average Volume
1.56 million shs
Market Capitalization
$390.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.20

Emergent BioSolutions MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
300.5% Upside
$31.20 Price Target
Short Interest
Bearish
13.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.40
Upright™ Environmental Score
News Sentiment
-0.08mentions of Emergent BioSolutions in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.22) to $1.08 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

277th out of 986 stocks

Pharmaceutical Preparations Industry

118th out of 477 stocks


EBS stock logo

About Emergent BioSolutions (NYSE:EBS) Stock

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Stock News Headlines

Penny Stock Shows Big Potential
The $4.37 trillion wellness market and the little-known penny stock to get on radar now.
Penny Stock Shows Big Potential
The $4.37 trillion wellness market and the little-known penny stock to get on radar now.
Q4 2022 Emergent BioSolutions Inc Earnings Call
Emergent Biosolutions Q4 2022 Earnings Preview
Earnings Outlook For Emergent BioSolutions
See More Headlines
Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Company Calendar

Last Earnings
2/27/2023
Today
3/23/2023
Next Earnings (Estimated)
4/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
CUSIP
29089Q10
Employees
2,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$31.20
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+300.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

Net Income
$-223,800,000.00
Pretax Margin
-19.78%

Debt

Sales & Book Value

Annual Sales
$1.12 billion
Cash Flow
$0.68 per share
Book Value
$27.72 per share

Miscellaneous

Free Float
44,574,000
Market Cap
$390.59 million
Optionable
Optionable
Beta
0.94

Key Executives

  • Robert G. Kramer
    President, Chief Executive Officer & Director
  • Adam Robert Havey
    Chief Operating Officer & EVP-Business Operations
  • Richard Scott LindahlRichard Scott Lindahl
    Chief Financial Officer, Treasurer & Executive VP
  • Sharon M. Solomon
    Chief Information Officer & Senior Vice President
  • Christopher H. Cabell
    Chief Medical Officer & Head-Clinical Development













EBS Stock - Frequently Asked Questions

Should I buy or sell Emergent BioSolutions stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares.
View EBS analyst ratings
or view top-rated stocks.

What is Emergent BioSolutions' stock price forecast for 2023?

6 Wall Street research analysts have issued 12 month target prices for Emergent BioSolutions' stock. Their EBS share price forecasts range from $9.00 to $55.00. On average, they anticipate the company's stock price to reach $31.20 in the next twelve months. This suggests a possible upside of 300.5% from the stock's current price.
View analysts price targets for EBS
or view top-rated stocks among Wall Street analysts.

How have EBS shares performed in 2023?

Emergent BioSolutions' stock was trading at $11.81 on January 1st, 2023. Since then, EBS stock has decreased by 34.0% and is now trading at $7.79.
View the best growth stocks for 2023 here
.

When is Emergent BioSolutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our EBS earnings forecast
.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) released its quarterly earnings results on Monday, February, 27th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of $0.31 by $0.62. The biopharmaceutical company had revenue of $330.70 million for the quarter, compared to analysts' expectations of $298.23 million. Emergent BioSolutions had a negative net margin of 19.97% and a negative trailing twelve-month return on equity of 7.57%. The firm's quarterly revenue was down 54.3% on a year-over-year basis. During the same period in the previous year, the company earned $4.50 earnings per share.

What guidance has Emergent BioSolutions issued on next quarter's earnings?

Emergent BioSolutions updated its FY 2023 earnings guidance on Monday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.10 billion-$1.20 billion, compared to the consensus revenue estimate of $1.18 billion.

What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?

38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

What is Emergent BioSolutions' stock symbol?

Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Who are Emergent BioSolutions' major shareholders?

Emergent BioSolutions' stock is owned by a number of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (3.69%), Man Group plc (1.76%), Geode Capital Management LLC (1.72%), Charles Schwab Investment Management Inc. (1.39%), Morgan Stanley (1.31%) and AQR Capital Management LLC (1.10%). Insiders that own company stock include Adam Havey, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Richard S Lindahl, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi.
View institutional ownership trends
.

How do I buy shares of Emergent BioSolutions?

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Emergent BioSolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $7.79.

How much money does Emergent BioSolutions make?

Emergent BioSolutions (NYSE:EBS) has a market capitalization of $390.59 million and generates $1.12 billion in revenue each year. The biopharmaceutical company earns $-223,800,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis.

How many employees does Emergent BioSolutions have?

The company employs 2,500 workers across the globe.

How can I contact Emergent BioSolutions?

Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The official website for the company is www.emergentbiosolutions.com. The biopharmaceutical company can be reached via phone at (240) 631-3200, via email at burrowsr@ebsi.com, or via fax at 301-795-1899.

This page (NYSE:EBS) was last updated on 3/23/2023 by MarketBeat.com Staff